Page 179 - Interactive Theoritical Notes of Bioharmaceutics and pharamcokinetics.docx compressed
P. 179

PharmD clinical pharmacy program            Level 3, Semester 2          Biopharmaceutics & Pharmacokinetics (PT608(

                 Difference between linear and nonlinear pharmacokinetics



                                  Linear                                         Nonlinear
                        (Dose-independent)                               (Dose-dependent)



                     ADME all obey first-order kinetics.            At least one of the ADME processes is

                                                                  saturable.



                     PK  parameters  (Vd,  Cl,  t ½,  K)  are       One or more of the PK parameters are

                     constant.                                    dose dependent.



                     AUC is  directly proportional  to  the         AUC is disproportional to the dose.

                     dose.


                     Concentration  vs.  time  profile  is          Concentration  vs.  time  profile  is  not

                     superimposable for all doses.                superimposable for different doses.








                     1.  Elimination of drug does not follow simple first-order kinetics that is, elimination kinetics are
                        nonlinear.

                     2.  The  elimination  half-life  changes  as  dose  is  increased.  Usually,  the  elimination  half-life
                        increases  with  increased  dose  due  to  saturation  of  an  enzyme  system.  However,  the

                        elimination  half-life  might  decrease  due  to  “self”-induction  of  liver  biotransformation

                        enzymes, as is observed for carbamazepine.
                     3.  The area under the curve (AUC) is not proportional to the amount of bioavailable drug.

                     4.  The saturation of capacity-limited processes may be affected by other drugs that require the
                        same enzyme or carrier-mediated system (i.e., competition effects).

                     5.  The composition and/or ratio of the metabolites of a drug may be affected by a change in the
                        dose.



                                                                178
   174   175   176   177   178   179   180   181   182   183   184